Year All20242023202220212020 April 12, 2024 Invivyd Announces CEO Transition April 4, 2024 Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million March 28, 2024 Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights March 22, 2024 Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial March 22, 2024 Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19 February 5, 2024 Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference January 3, 2024 Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
